Skip to main content

P. Jeffrey Conn Archives

Investigational new drug for Alzheimer’s scheduled for first study in humans

Dec. 27, 2016—Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.

Read more


Foundation’s support speeds search for new schizophrenia drugs at Vanderbilt

Aug. 15, 2016—Research in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) aimed at developing innovative new treatments for schizophrenia just received a powerful assist from The William K. Warren Foundation.

Read more


Grant enhances mental illness drug research efforts

Jul. 16, 2015—Research at Vanderbilt University Medical Center aimed at developing potential new treatments for major depressive disorder, general anxiety disorder and post-traumatic stress disorder got a big boost this week from The William K. Warren Foundation of Tulsa, Oklahoma.

Read more


New schizophrenia drug candidates entering prep for first-in-human testing

Dec. 15, 2011—The progression of new drug candidates for schizophrenia with partner Janssen Pharmaceutica is the latest evidence that a new collaborative model for drug discovery pioneered at Vanderbilt may help identify and develop innovative candidate drugs for treatment of major brain disorders.

Read more


Upcoming Events

MORE EVENTS »